Jiangsu Changyou Environmental Protection Technology
301557
Hefei conver Holding
603409
LIERDA
832149
4
SHENGNAN TECHNOLOGY
837006
5
CHK
831167
US Stock MarketDetailed Quotes
TRVI Trevi Therapeutics
- 4.250
- -0.010-0.23%
Trading Mar 4 10:58 ET
379.80MMarket Cap-9.66P/E (TTM)
4.520High4.220Low546.00KVolume4.260Open4.260Pre Close2.38MTurnover0.82%Turnover RatioLossP/E (Static)89.37MShares5.05052wk High6.44P/B282.12MFloat Cap2.30052wk Low--Dividend TTM66.38MShs Float10.620Historical High--Div YieldTTM7.04%Amplitude0.460Historical Low4.362Avg Price1Lot Size
Trending Stocks
Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve
Moo Earnings
Feb 2 12:39
AMZN earnings preview: Grab rewards by guessing the opening price!
Trevi Therapeutics Stock Forum
Can Trevi's Haduvio Break Through Where Others Failed? Key IPF Cough Trial Fully Enrolled
Trevi Therapeutics Completes Enrollment for Phase 2B Coral Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients With Chronic Cough! Results expected in first half of 2025
📊⚡️📊
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Thursday, 12th December at 7:30 am
Independent Data Monitoring Statistician reaffirmed current sample size to remain at N=160
The trial has reached 75% of the targeted enrollment, and topline results continue to be expected in the first half of 20...
Trevi Therapeutics Announces Positive Outcome From SAMPLE Size Re-Estimation Resulting in No Change to the Current SAMPLE Size for the Phase 2B Coral Trial in Idiopathic Pulmonary Fibrosis Patients With Chronic Cough
No comment yet